Every announcement Glenmark Pharmaceuticals has filed with the exchanges that we have reported, newest first. Each story links the original filing.
Price
₹2415
Market Cap
₹68,157.27 Cr
Revenue TTM
₹17,736.55 Cr
P/E (TTM)
37.91×
Sector 49.16×
Reference data from Trendlyne, as of the most recent story. Not a valuation or a recommendation.
Glenmark Pharmaceuticals Launches RYALTRIS Nasal Spray in Brazil; Targets 60 Million Patients
Glenmark Pharmaceuticals launches RYALTRIS nasal spray in Brazil, targeting a patient pool of 60 million. The product is now approved in 57 global ma…
Glenmark Pharma Launches Calcium Gluconate Injection in US Market Worth $69.9 Million
Glenmark Pharmaceuticals launches Calcium Gluconate Injection USP in the US, targeting a $69.9M market. This expands the company's hospital product p…
Glenmark Pharmaceuticals Advances Phase 3 Trial for Trastuzumab rezetecan in Ovarian Cancer
Glenmark Pharmaceuticals initiates Phase 3 enrollment in India for Trastuzumab rezetecan, targeting ovarian cancer. TTM revenue stands at ₹16,982.51 …
Glenmark Pharmaceuticals Launches Lacosamide Injection in USA Targeting $15.2M Market
Glenmark Pharmaceuticals launches Lacosamide Injection USP in the US market, targeting annual sales of $15.2 million. Learn about this strategic port…
Track Glenmark Pharmaceuticals in real time
ALFA Finder watches NSE & BSE filings 24/7 and alerts you the moment Glenmark Pharmaceuticals files something material.
Start Free — 15-day trial